Remaking Roche
How the once-dominant cancer company has overhauled its strategy for long-term growth
For nearly two decades, Roche held a position as a powerhouse among cancer companies. But as the Swiss pharma navigates a monumental patent cliff, it’s being forced to carve a new future — one marked with potential growth drivers that extend beyond its traditional stronghold to at least three other disease areas, where its hallmark may be defined by specific products and indications rather than a single area of dominance.
The move away from oncology is not due to a lack of trying. Roche (SIX:ROG; OTCQB:RHHBY) attempted to maintain its leadership position in cancer by keeping its clinical pipeline stocked. However, like other companies that were late to the PD-1/PD-L1 race and then bet big on immunotherapy combinations, few of those opportunities have panned out. ...